Patent SG-11201903155X-A (SG)
Title: Pharmaceutical compounds
Inventor: PEGG NEIL ANTHONY
IPC: A61K31/422
Filed: 2017-10-18
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 April 2018 (26.04.2018) WIP0 I PCT ill 1111u°11101VIIIVIIIVIIIolo olomll Em Immo oimIE (10) International Publication Number WO 2018/073586 Al (51) International Patent Classification: CO7D 413/14 (2006.01) A61K 31/422 (2006.01) CO7D 471/04 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/GB2017/053152 (22) International Filing Date: 18 October 2017 (18.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1617630.7 18 October 2016 (18.10.2016) GB (71) Applicant: CELLCENTRIC LTD [GB/GB]; Chester- ford Research Park, Little Chesterford, Cambridge Cam- bridgeshire CB10 1XL (GB). (72) Inventors: PEGG, Neil Anthony; c/o CellCentric Lim- ited, Chesterford Research Park, Little Chesterford, Cam- bridge Cambridgeshire CB10 1XL (GB). ONIONS, Stu- art Thomas; c/o Sygnature Discovery Limited, BioCity, Pennyfoot Street, Nottingham Nottinghamshire NG1 1GF (GB). TADDEI, David Michel Adrien; c/o Sygnature Discovery Limited, BioCity, Pennyfoot Street, Nottingham Nottinghamshire NG1 1GF (GB). SHANNON, Jonathan; c/o Sygnature Discovery Limited, BioCity, Pennyfoot Street, Nottingham Nottinghamshire NG1 1GF (GB). PAO- LETTA, Silvia; c/o Sygnature Discovery Limited, BioCity, Pennyfoot Street, Nottingham Nottinghamshire NG1 1GF (GB). BROWN, Richard James; c/o Sygnature Discov- ery Limited, BioCity, Pennyfoot Street, Nottingham Not- tinghamshire NG1 1GF (GB). SMYTH, Don; c/o Sygna- ture Discovery Limited, BioCity, Pennyfoot Street, Not- tingham Nottinghamshire NG1 1GF (GB). HARBOTTLE, Gareth; c/o Sygnature Discovery Limited, BioCity, Penny- foot Street, Nottingham Nottinghamshire NG1 1GF (GB). (74) Agent: KEEN, Celia Mary; 14 South Square, Gray's Inn, London Greater London WC1R 5JJ (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 2 I (3)) (54) Title: PHARMACEUTICAL COMPOUNDS W O 20 18/07 35 86 Al (I) (57) : A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.